David Roodman, MD, PhD from Indiana University Simon Cancer Center, Indianapolis, IN, discusses the challenges of myeloma-induced bone disease. Multiple myeloma is the type of cancer that most frequently causes bone disease, with 70% of patients presenting bone involvement and 20% with pathological fractures at diagnosis. Over the course of the disease, 85% of patients will have bone involvement, which causes various challenges for patients including severe pain, decreased quality of life and increased risk of mortality. Imaging and vitamin D monitoring also pose a significant challenge that must be addressed.
Recorded at the 2017 European Multiple Myeloma Academy (EMMA) in Vienna, Austria.
This program was sponsored by Celgene through an unrestricted educational grant to Video Journal of Hematological Oncology.